Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Rhea-AI Summary

Tevogen (NASDAQ:TVGN) has revealed significant valuation metrics for its pipeline product TVGN 930, targeting EBV-associated leukemia and lymphomas. The company projects a risk-adjusted Net Present Value (rNPV) exceeding $250 million in the US market alone, with an estimated 5-year cumulative revenue forecast of $3.5 billion.

The therapeutic candidate addresses an accessible US market of up to 40,000 patients across five rare disease indications. Notably, TVGN 930 aims to fill a significant therapeutic gap, as there are currently no approved EBV vaccines or effective treatments. The company's development approach leverages a unique, faster, and cost-efficient drug development model.

Positive

• None.

Negative

• Additional capital raising may be needed to execute business plan
• Limited operating history increases execution risk
• Multiple regulatory and clinical development risks ahead
• Potential challenges in maintaining effective internal controls

Insights

Oncology & Biotech Investment Specialist

Tevogen's EBV cancer therapy TVGN 930 shows $250M valuation potential and $3.5B five-year revenue forecast, targeting underserved rare disease market.

Tevogen has unveiled significant financial projections for their TVGN 930 therapy, targeting Epstein-Barr Virus (EBV) associated blood cancers. The company estimates a risk-adjusted Net Present Value (rNPV) exceeding $250 million in the US market alone, with cumulative 5-year revenue potentially reaching $3.5 billion. These figures highlight substantial commercial potential for a therapy addressing a critical unmet need.

The market opportunity is compelling - TVGN 930 targets five rare disease indications with an accessible patient population of up to 40,000 in the US. This positions the therapy within the valuable rare disease space, where treatments often command premium pricing due to limited patient populations and high unmet needs.

What's particularly noteworthy is Tevogen's emphasis on their development model, which they claim enables faster, more cost-efficient drug development. This approach appears to be validated by their prior success with TVGN 489 for immunocompromised COVID-19 patients, suggesting their platform may have broader applications.

The company's Chief Commercial Officer highlights that no approved EBV vaccines currently exist (as of July), creating a significant therapeutic gap that TVGN 930 aims to fill. This absence of effective options for oncologists treating EBV-related malignancies strengthens Tevogen's market positioning.

Beyond the current indications, Tevogen indicates potential expansion into multiple sclerosis through EBV control, which could substantially increase the addressable market. This represents a classic pipeline-in-a-product strategy that could amplify the asset's value if successful.

While these projections show promise, investors should note these are company-provided estimates with inherent uncertainty. The risk-adjusted valuation methodology incorporates success probabilities at various development stages, but actual market performance will depend on clinical results, regulatory approval, and competitive dynamics in this specialized oncology space.

• The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.
• Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.
• Focused on improved prognosis for patients with hematologic malignancies.
  

WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV).

The TVGN 930 cumulative 5-year top-line revenue forecast is estimated to be ~$3.5 billion. The forecast reflects the Company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. The current rNPV projection for this internally developed asset exceeds ~$250 million. This is based on our current understanding of the unmet medical needs and the competitive landscape. The risk adjustment resets for every milestone reached in the product development lifecycle and Tevogen’s success for its first clinical stage product, TVGN 489, for the treatment of SARS-CoV-2 in immunocompromised patients, highlights the rapid pace which this can be accomplished.

Treatment of multiple sclerosis through tighter EBV control could be an additional opportunity for this product. The Company will share additional valuation updates on product pipeline as well as its other assets.

“As of July, of this year, there are no approved vaccines for EBV. This together with the absence of effective therapeutics poses a significant challenge for oncologists treating these malignancies” said Sadiq Khan, Chief Commercial Officer of Tevogen Bio. “TVGN 930 offers a significant opportunity to fill this therapeutic gap”.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

FAQ

What is the projected market value of Tevogen's TVGN 930 drug candidate?

TVGN 930's risk-adjusted Net Present Value (rNPV) is estimated to exceed $250 million in the US market, with a projected 5-year cumulative revenue of ~$3.5 billion.

How many patients could potentially benefit from Tevogen's TVGN 930 treatment?

TVGN 930 targets an accessible market of up to 40,000 patients in the US across five rare disease indications related to EBV-associated leukemia and lymphomas.

What makes TVGN 930 unique in the current market?

TVGN 930 addresses a significant therapeutic gap as there are currently no approved vaccines for EBV or effective therapeutics for treating EBV-associated malignancies.

What are the main risks facing Tevogen's TVGN 930 development?

Key risks include the need for additional capital, limited operating history, regulatory approval challenges, and potential difficulties in clinical development and commercialization.

What additional opportunities exist for Tevogen's TVGN 930?

Beyond its primary indications, TVGN 930 has potential applications in treating multiple sclerosis through tighter EBV control, representing an additional market opportunity.